Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer

Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response to taxane-based therapies in several cancer types, but its relevance in prostate cancer is unknown. In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC cancer 2019-03, Vol.19 (1), p.193-193, Article 193
Hauptverfasser: Schroeder, Cornelia, Grell, Jan, Hube-Magg, Claudia, Kluth, Martina, Lang, Dagmar, Simon, Ronald, Höflmayer, Doris, Minner, Sarah, Burandt, Eike, Clauditz, Till S, Büscheck, Franziska, Jacobsen, Frank, Huland, Hartwig, Graefen, Markus, Schlomm, Thorsten, Sauter, Guido, Steurer, Stefan
Format: Artikel
Sprache:eng
Schlagworte:
Biochemistry
Cancer research
Cancer treatment
Deletion
EDTA
ERG
Fluorescence
Gene expression
Genetic aspects
Immunohistochemistry
MAPT
Microtubules
Prognosis
Prostate cancer
PTEN
Tau
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Microtubule-associated protein Tau (MAPT) overexpression has been linked to poor prognosis and decreased response to taxane-based therapies in several cancer types, but its relevance in prostate cancer is unknown. In this study, MAPT expression was analyzed by immunohistochemistry on a tissue microarray containing 17,747 prostate cancers. MAPT was absent in normal prostate epithelial cells but detectable in 1004 (8.2%) of 12,313 interpretable cancers. Its expression was associated with advanced tumor stage, high Gleason grade, positive lymph nodes, and early biochemical recurrence (p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-019-5390-1